← FDA DRUG APPROVALS

FDA ANDA · ANDA205447

BENDAMUSTINE HYDROCHLORIDE

Sponsor: BRECKENRIDGE

APPLICATION
ANDA205447
TYPE
ANDA
ORIGINAL APPROVAL
2023-02-14
LATEST ACTION
2023-02-14
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Discontinued

Products

BENDAMUSTINE HYDROCHLORIDEDiscontinued
BENDAMUSTINE HYDROCHLORIDE 25MG/VIAL · POWDER · INTRAVENOUS
BENDAMUSTINE HYDROCHLORIDEDiscontinued
BENDAMUSTINE HYDROCHLORIDE 100MG/VIAL · POWDER · INTRAVENOUS

Approval history

2023-02-14UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →